Mineralys Therapeutics had positive results with lorundrostat for hypertension treatment.

From GlobeNewswire: 2025-03-29 14:30:00

Mineralys Therapeutics, Inc. announced that lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction in blood pressure at week 12, with a favorable safety profile. Lorundrostat is a selective aldosterone synthase inhibitor with promising results for high-risk patients with uncontrolled hypertension. The Advance-HTN trial showcased the potential of lorundrostat as a best-in-class treatment. The trial enrolled patients with a high burden of resistant hypertension, with favorable safety and tolerability outcomes. Mineralys plans to present additional data from the Phase 3 Launch-HTN trial at an upcoming medical conference.

The Phase 2 Advance-HTN trial evaluated the efficacy and safety of lorundrostat in patients with uncontrolled or resistant hypertension. The trial demonstrated significant reductions in blood pressure at week 12 with lorundrostat 50 mg. The drug showed modest changes in potassium, sodium, and eGFR, along with a low discontinuation rate. The safety profile of lorundrostat in the trial was favorable, with manageable on-target effects on serum electrolytes and a low incidence of drug-related serious adverse events.

Mineralys Therapeutics will host a conference call on April 1, 2025, to discuss the detailed results from the Advance-HTN trial. The Company is focused on developing medicines to target hypertension, CKD, and OSA driven by dysregulated aldosterone. Lorundrostat, a highly selective aldosterone synthase inhibitor, is showing promise as a novel treatment for hypertension. The drug demonstrated significant blood pressure reductions in patients with uncontrolled or resistant hypertension, highlighting its potential as a well-tolerated therapy for patients in need.



Read more at GlobeNewswire: Mineralys Therapeutics Announces Late-Breaking Data from